Premium
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)
Author(s) -
HOFFMANN M. M.,
WINKLER K.,
RENNER W.,
WINKELMANN B. R.,
SEELHORST U.,
WELLNITZ B.,
BOEHM B. O.,
MÄRZ W.
Publication year - 2009
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2008.03216.x
Subject(s) - medicine , haplotype , coronary artery disease , odds ratio , lipoprotein associated phospholipase a2 , allele , disease , genotype , cardiology , gastroenterology , endocrinology , oncology , lipoprotein , gene , genetics , biology , cholesterol
Summary. Background: There is increasing evidence that lipoprotein‐associated phospholipase A2 (LpPLA2) is associated with cardiovascular disease. However, it is still unclear whether LpPLA2 is simply a marker or has a causal role as either a pro‐ or anti‐atherogenic factor. Methods: We analyzed the association of five polymorphisms (−1357G>A, −403T>C, Arg92His, Ile198Thr, Ala379Val) and related haplotypes at the PLA2G7 locus with angiographic coronary artery disease (CAD), plasma LpPLA2 activity, and long‐term survival in 3234 patients scheduled for coronary angiography. Results: The promoter variant −403C and His 92 were associated with a decrease and Val 379 with an increase in plasma LpPLA2 activity. Both coding variants revealed a clear gene‐dose effect. Interestingly, the rare Thr 198 allele, which was not associated with any change in plasma LpPLA2 activity, was more frequent in subjects without CAD ( P = 0.009), with an adjusted odds ratio for CAD of 0.69 (95% CI: 0.49–0.96; P = 0.029). None of the analyzed variants showed any robust association with all‐cause or cardiovascular mortality. Conclusion: Irrespective of the significant association between some variants with plasma LpPLA2 activity, it is still unclear whether these polymorphisms or haplotypes are associated with the risk and outcome of cardiovascular disease in Caucasians.